Free NewsletterPro Login

Warning: Undefined variable $stocks in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 448

Warning: foreach() argument must be of type array|object, null given in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 448

Warning: Undefined variable $funds in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 472

Warning: foreach() argument must be of type array|object, null given in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 472
/* the link was here */
×
Free investor livestream — Nov 17

How To Use ChatGPT & Claude To Research Stocks Like A Pro

01
The prompt we use to break down any stock
02
How to fact-check what AI tells you
03
How to compare two stocks in minutes

Short Seller Calls Abivax Drug a Toxin, Shares Slide 17% in Paris

Published Nov 20, 2026
Share:
Summary:
  • Scorpion Capital, in a post on X, said that Abivax's ulcerative colitis candidate, obefazimod, is fat soluble like banned pesticides and industrial chemicals; it also claimed its lab work suggests the compound could act as a photocarcinogen.
  • Abivax pushed back late Friday, saying the report "contains numerous factually inaccurate and misleading statements, assumptions, and conclusions, including those based on studies commissioned and funded by Scorpion Capital itself," and reiterated plans to seek US Food and Drug Administration approval by yearend.
  • Shares fell 17% in Paris on Friday, taking the year-to-date decline to 48%.

What Scorpion alleged

Scorpion Capital Partners LP labeled obefazimod a toxin and, in a post on X, argued its fat solubility resembles that seen in prohibited pesticides and some industrial compounds, a characteristic it says Abivax omitted to disclose. The short seller also said its own lab tests suggest the drug could be a photocarcinogen, meaning a substance that may trigger cancer following light exposure. It further asserted that much of Abivax's research leans on studies published in China and cited a scientific paper that was later retracted.

How Abivax responded

Abivax countered late Friday, saying the analysis "contains numerous factually inaccurate and misleading statements, assumptions, and conclusions, including those based on studies commissioned and funded by Scorpion Capital itself." The company said it stands by its clinical results and still plans to submit an application to the US Food and Drug Administration before yearend.

The backdrop and what moved the stock

Cancer risk has been a recurring worry around obefazimod in inflammatory bowel disease. Abivax has previously reported cancer cases in an ulcerative colitis study, noting the tumors occurred in patients already at risk and, in some instances, in those with a prior history of skin cancer. The same drug is also in testing for Crohn's disease. Shares dropped 17% in Paris on Friday, extending their year-to-date slide to 48%.

When uncertainty surrounds company news and analysis, sign up for the free Market Briefs newsletter that arrives each morning

Why it matters for investors

Abivax has long been a takeover talking point, which has amplified its price swings. Before the obefazimod trial readout, the stock climbed on hopes that positive data would unlock a large market. The latest short call hit an already volatile name, reminding portfolios that binary drug headlines can overwhelm fundamentals in the short run.

When headlines about drugs and disclosures appear, sign up for the free daily Market Briefs to get clear context in minutes

Disclosure

Recent News

1 2 3 … 133

Get Market Briefs delivered to your inbox every morning for free!

No fluff. No noise. No politics. Just finance news you can read in 5 minutes.

Blogs

November 20, 2026
Anthropic Stock at $1.5 Trillion: Why This IPO Isn't Amazon in 1997

Anthropic has gone public at a valuation of about $1.5 trillion, while Amazon went public in 1997 at around $440 million. Anthropic has about $33 billion in revenue this year and no profit, and investors are paying more than 40 times its sales, against about 3 times for Amazon. Briefs Finance CEO Jaspreet Singh says nobody knows what comes next, and that long-term investors use downturns to buy instead of panic selling.

Read More
November 17, 2026
Is the Stock Market Going to Crash? Why Nvidia and the Fed Have Investors on Edge
  • Tech stocks are selling off because investors don't know who will lead Nvidia, the company that has been funding the AI industry and selling it chips.
  • Inflation has the Federal Reserve planning to raise interest rates, with a hike expected in December, and that puts pressure on homebuyers, private equity and the $40 trillion national debt.
  • Briefs Finance CEO Jaspreet Singh says nobody has a crystal ball, so his rules are to buy when markets are low, hold long term and invest only what you're willing to lose.
Read More
November 16, 2026
The $40 Trillion National Debt: Trump's 4-Part Plan to Make It Feel Smaller
  • The national debt is above $40 trillion, and the Federal Reserve has gone from sending Washington its profits to losing money.
  • President Trump's four-part plan leans on shorter-term debt, stablecoin companies buying Treasuries, a bigger balance sheet and government stakes in private companies.
  • The goal is to outgrow the debt, not pay it off, so Jaspreet Singh points investors to the seven industries where Washington wants growth.
Read More
November 16, 2026
The Fed Is Talking About a Jumbo Interest Rate Hike. It Has No Easy Way Out
  • The Fed makes its next rate decision on December 9 and is now talking about jumbo interest rate hikes of 0.5%, though one in December looks unlikely.
  • Washington will pay a record $1.05 trillion in interest this year on $40 trillion of debt, and that debt resets at higher rates as the Fed hikes.
  • Jaspreet Singh's five moves are to pay down variable-rate debt, earn interest on your savings, know which stocks feel the pressure, look at value and hedge.
Read More
November 16, 2026
Buying on Margin Is at a Record High. Here's the Risk for the Stock Market
  • Margin debt, the money investors borrow to buy stocks, is at a record of around 4.6% of GDP, up from 3.9% in 2021.
  • ETF money has more than tripled in five years to 7% of GDP, while corporate buybacks and 401(k) money sit below their earlier peaks.
  • Margin calls and panic selling can make the next downturn deeper, so Jaspreet Singh keeps buying broad market funds and says most investors should skip margin debt.
Read More
November 16, 2026
Housing Prices Are Falling. Buying a House Still Isn't Cheaper
  • Housing prices have fallen for four straight weeks, but mortgage rates around 7.2% keep the monthly payment about where it was in 2023.
  • Talk of a jumbo Fed rate hike and a plan to sell Fannie Mae and Freddie Mac on the stock market could both push mortgage rates higher.
  • Briefs Finance CEO Jaspreet Singh treats a house as a liability: buy within your budget and let your investments build the wealth.
Read More
November 14, 2026
Nvidia News: Jensen Huang Is Out, and the "Bank" Behind American AI Just Lost Its Founder
  • Jensen Huang is out at Nvidia over affairs with multiple people, and the company he founded has been the bank of American AI, with about $30 billion into OpenAI and $10 billion into Anthropic.
  • A hotter-than-expected inflation report has Fed officials talking about a possible 0.5% hike in December, and gold, silver, and bitcoin fell on the news.
  • President Trump said the US may not need a deal with Iran, keeping oil prices and inflation risk high. Jaspreet Singh breaks down what it all means for AI stocks and your portfolio.
Read More
November 14, 2026
Record Highs, a 57-Year Low in Jobless Claims, and a Stock Market Bubble: Inside the Weirdest Market in History
  • Stocks are booming at the fastest pace in years, jobless claims just hit a 57-year low, and most investors still feel like nobody is hiring.
  • The Fed is protecting the dollar over the economy, oil swings on every Iran headline, and a few AI companies are carrying an S&P 500 where four of five stocks sit in a correction.
  • Jaspreet Singh explains why circular financing between Nvidia, OpenAI, Anthropic, and SpaceX rhymes with 2008's house of cards, and how his three investing pillars handle a stock market bubble.
Read More
November 14, 2026
Is a Recession Coming? The Fed Just Made a U-Turn It Has Only Made Twice in 60 Years
  • The Fed has raised rates, cut them, then raised them again only twice in the last 60 years, and both times the economy fell into a recession and stocks crashed.
  • The same stop-and-go cycle is playing out now, with one big difference: US debt is 125% of GDP today versus about 30% in 1980.
  • In the 1970s gold rose roughly 24x, real estate 157%, stocks lagged, and cash lost half its value. Jaspreet Singh lays out five assets to consider before the next flip.
Read More
November 14, 2026
The 2027 Tax Brackets Are Out: How Some Investors Can Earn $135,300 and Pay $0
  • The IRS 2027 tax plan keeps the same seven rates but widens every bracket and lifts the married-filing-jointly standard deduction to $33,200.
  • The 0% long-term capital gains bracket rises to $102,100, so a household living on $135,300 of investment income could owe $0 in federal income tax.
  • C corporations still pay 21%, small businesses keep the 20% QBI deduction, and the 401(k) limit climbs to $25,500 with an $8,500 catch-up for investors over 50.
Read More
1 2 3 … 33
Share via
Copy link